埃达珠单抗(INN:Etaracizumab;开发代号:MEDI-522),或译伊瑞西珠单抗,商品名Abegrin,是一种人源化单克隆抗体,正在研究用于治疗转移性黑色素瘤、前列腺癌、[1]卵巢癌[2]和各种其他类型的癌症。[3]它是由MedImmune生产的。[1]
它是Vitaxin(也称为MEDI-523)的增强版。两者均源自小鼠抗体LM609。[4]
- ^ 1.0 1.1 Etaracizumab (PDF). Statement On A Nonproprietary Name Adopted By The Usan Council. [2023-12-27]. (原始内容存档 (PDF)于2012-03-19).
- ^ Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. November 2008, 10 (11): 1259–67. PMC 2570602
. PMID 18953435. doi:10.1593/neo.08740. - ^ Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Investigational New Drugs. February 2008, 26 (1): 35–43. PMID 17876527. S2CID 37221398. doi:10.1007/s10637-007-9077-0.
- ^ McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research. November 2005, 11 (21): 7851–60. PMID 16278408. doi:10.1158/1078-0432.CCR-05-0262.